The reason drug trials and genetic studies show different heart benefits from lowering cholesterol might be because one looks at short-term drug use and the other looks at lifelong low cholesterol.
Scientific Claim
The difference in cardiovascular event reduction estimates between randomized clinical trials (22–24%) and Mendelian studies (55%) may arise from differences in study design, including duration of exposure and patient characteristics.
Original Statement
“Such a difference does not come as a surprise, with RCTs and Mendelian studies being different in many respects; in particular, Mendelian studies randomize patients according to genotype and look at patient exposure to risk factors or treatments over a timespan that is only exceptionally contemplated by RCTs (Ference et al., 2019; Gill et al., 2020).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design cannot support claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The abstract uses 'does not come as a surprise' and 'being different in many respects' — descriptive language appropriate for a narrative review. No causal or probabilistic claims are made.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aIn EvidenceWhether differences in exposure duration and population characteristics systematically explain the disparity in effect sizes between RCTs and Mendelian studies.
Whether differences in exposure duration and population characteristics systematically explain the disparity in effect sizes between RCTs and Mendelian studies.
What This Would Prove
Whether differences in exposure duration and population characteristics systematically explain the disparity in effect sizes between RCTs and Mendelian studies.
Ideal Study Design
A meta-regression of 30+ RCTs and 10+ Mendelian studies, modeling effect size as a function of treatment duration, baseline LDL-C, age, and genetic variant strength, with adjustment for publication bias.
Limitation: Cannot prove causation; relies on aggregated data with heterogeneous definitions.
Prospective Cohort StudyLevel 2aIn EvidenceHow the duration of LDL-C exposure influences CV risk reduction in real-world populations with and without pharmacotherapy.
How the duration of LDL-C exposure influences CV risk reduction in real-world populations with and without pharmacotherapy.
What This Would Prove
How the duration of LDL-C exposure influences CV risk reduction in real-world populations with and without pharmacotherapy.
Ideal Study Design
A cohort of 20,000 individuals with lifelong LDL-C trajectories (from childhood to age 70) stratified by statin use, with CV events tracked and exposure duration quantified in years of exposure.
Limitation: Cannot control for unmeasured confounders like diet or physical activity over decades.
Case-Control StudyLevel 3aIn EvidenceWhether individuals with long-term low LDL-C (genetic or pharmacological) have lower CV risk than those with short-term lowering.
Whether individuals with long-term low LDL-C (genetic or pharmacological) have lower CV risk than those with short-term lowering.
What This Would Prove
Whether individuals with long-term low LDL-C (genetic or pharmacological) have lower CV risk than those with short-term lowering.
Ideal Study Design
A case-control study of 1,000 individuals with early-onset CVD vs 1,000 controls, comparing duration of LDL-C lowering (via genetic score or medication history) and cumulative exposure (LDL-C × years).
Limitation: Retrospective recall bias in medication history; limited power for rare outcomes.
Evidence from Studies
Supporting (1)
LDL Cholesterol and Cardiovascular Events in a Population Network: One More Twist of an Endless Story
The study says the reason some studies show a bigger heart benefit from lowering cholesterol is because they look at people who’ve had low cholesterol their whole life (due to genes), not just people taking pills for a year or two.